This study showed that pembrolizumab plus chemotherapy prolonged the OS and PFS better than chemotherapy alone in previously untreated patients with metastatic non-squamous NSCLC without EGFR or ALK mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.